Company news
Design Therapeutics, Inc. news in 2022
Design Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
December 6, 2022
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
November 2, 2022
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
October 16, 2022
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
September 21, 2022
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
August 7, 2022
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
August 2, 2022
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
May 31, 2022
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
May 8, 2022
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia
March 29, 2022
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
March 9, 2022
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
March 8, 2022
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
February 27, 2022
Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 9, 2022
Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
January 31, 2022